Novel and Innovative Drug Delivery Systems to Overcome Chemoresistance in Human Malignancies addresses the critical challenge of cancer chemoresistance, synthesizing insights from cancer biology, molecular biology, biotechnology, and nanotechnology. The book explores the complex mechanisms underlying drug resistance, including alterations in key signaling pathways and the tumor microenvironment's role in cancer cell survival. It highlights advancements in drug delivery technologies, such as nanomedicine and biomimetic strategies, which enhance drug targeting and minimize off-target effects. The integration of techniques like CRISPR-Cas9 and artificial intelligence in developing next-generation therapies is also emphasized.
For an academic audience, this book serves as an essential resource to foster interdisciplinary collaboration in cancer research. It equips researchers, clinicians, and industry professionals with the knowledge needed to navigate the evolving landscape of cancer therapeutics, addressing critical challenges in drug delivery and chemoresistance to improve patient outcomes.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1 Exploring chemoresistance mechanisms and innovative drug delivery approaches in effective cancer therapy2 Molecular interplay of hypoxia, aberrant angiogenesis, and immune suppression in cancer chemoresistance
3 Impact of hypoxia, angiogenesis, and immunosuppression in chemoresistance
4 Design and applications of smart biomaterials for anticancer drug delivery systems
5 Revolutionizing precision oncology: Combating chemoresistance with nanorobotics
6 Advanced drug delivery strategies: Nanoparticles, liposomes, dendrimers, and smart biomaterials
7 Epigenetic modulations in cancer chemoresistance: Harnessing nanotechnology for targeted therapy
8 Advancements in cancer immunotherapy: Targeting the tumor immune microenvironment (TIME)
9 Near-infrared responsive photothermal-immunotherapy for overcoming chemoresistance in cancer therapy
10 Combating chemoresistance through RNA-based therapeutic approaches: A mechanistic insight
11 Therapeutic potential of drug repurposing in reversing chemoresistance
12 Ion channels in chemoresistance: A mechanistic overview and CRISPR-based therapeutic strategies
13 CRISPR/Cas9 and gene editing approaches as a solution for chemoresistance
14 Clinical applications and emerging challenges of novel drug delivery systems
15 Exosome and extracellular vesicle-based therapeutics to overcome cancer chemoresistance
16 Preclinical strategies for investigating drug delivery platforms
17 Artificial intelligence and machine learning approaches in rational drug design to overcome cancer chemoresistance
18 Chemoresistance in modern oncology: A multilayered network of signaling, plasticity, and tumor microenvironmental interactions
Authors
Shuvomoy Banerjee Institute of Advanced Research (IAR), India.Dr. Shuvomoy Banerjee is an accomplished academic and researcher with extensive experience as an editorial board member for several reputable journals, including Reviews in Medical Virology, and as an associate editor for the IAR University Journal. He holds a Ph.D. in cancer biology from Bose Institute, Kolkata, and has post-doctoral research experience at the University of Pennsylvania and Beckman Research Institute. Currently an Assistant Professor at the Institute of Advanced Research, Gandhinagar, Dr. Banerjee specializes in cancer immunology and tumor virology. His prolific contributions include numerous publications in high-impact journals. He has led multiple extramural research projects funded by organizations such as the Science and Engineering Research Board (SERB) and the Gujarat State Biotechnology Mission. His active participation in various scientific organizations underscores his credibility and thought leadership in the field of cancer research.
Regenerate response Dhiraj Bhatia Indian Institute of Technology (IIT), India. Dr. Dhiraj Bhatia, an associate professor at IIT-Gandhinagar, specializes in DNA nanotechnology, chemical biology, and drug delivery systems. With a Ph.D. from NCBS-TIFR and postdoctoral work including an HFSP fellowship at Institut Curie, he has pioneered research in structural DNA nanotechnology for biomedical applications. His publications in high-impact journals like ACS Nano, Nature Nanotechnology, and Angewandte Chemie showcase his expertise. His work on programmable DNA nanodevices, hydrogels, and targeted drug delivery addresses critical challenges such as cancer chemoresistance. Recognized with awards like the Merck Young Scientist Award and INYAS-INSA Membership, Dr. Bhatia is also an experienced reviewer and mentor, actively organizing interdisciplinary conferences
